Skip to Content

(785) 505-5000

Bullectomy for COPD

Topic Overview

Chronic obstructive pulmonary disease (COPD) weakens the structure of the lung and may also damage the tiny air sacs (alveoli) in the lung. When these air sacs break down, larger airspaces known as bullae are formed.

Bullae sometimes can become so large that they interfere with breathing and may cause complications:

  • They can burst, leading to a collapsed lung (pneumothorax). A collapsed lung will often need treatment with a chest tube.
  • They can become infected, leading to an abscess in the lung that can spread to the pleural cavity (the space between the lung and the membrane that surrounds it). This condition (empyema) can be difficult to resolve and often requires extensive treatment with antibiotics.

For some people, surgically removing the enlarged air sacs—known as a bullectomy—makes breathing easier. But few people are considered good candidates for a bullectomy. It may work best for people with COPD who are young, have large bullae that are grouped in just one area of the lung, and do not have severe blockage in their airways. A bullectomy may be considered if the bullae:

  • Are larger than one-third of a lung.
  • Prevent the lung from expanding so the person cannot move enough air into his or her lungs.

Bullectomy may make the lungs work better so more oxygen gets into the blood.

If there are many bullae spread throughout the lungs, surgery is not likely to be helpful. In this case, other areas of the lung often become damaged after the surgery. The best surgical results happen when there is only one bulla or only a few that are all clustered in one area.

Long-term follow-up studies have begun to show that within 3 to 5 years after surgery, lung function deteriorates to the level it was before surgery.1

The decision about whether to do the surgery is difficult and usually is based on the doctor's experience and the person's overall condition.

Bullae can be removed using a laser. But this method has not been found to have an advantage over traditional surgery.

References

Citations

  1. Hanania NA, et al. (2003). The efficacy and safety of fluticasone propionate (250 micrograms)/salmeterol (50 micrograms) combined in the Diskus Inhaler for the treatment of COPD. Chest, 124: 834–843.

Credits

By Healthwise Staff
E. Gregory Thompson, MD - Internal Medicine
Ken Y. Yoneda, MD - Pulmonology
Last Revised February 19, 2013

Last Revised: February 19, 2013

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.

© 1995-2014 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.